Disease Landscape and Forecast Insights

The drug market for opioid-induced constipation (OIC) is served by a variety of prescription medications, including several agents that are approved for irritable bowel syndrome with constipation (…

Idiopathic pulmonary fibrosis (IPF) is an orphan disease affecting approximately 50,000 people in the United States. It is characterized by the thickening and stiffening of tissues in the lungs…

Clarivate’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key bladder cancer patient populations covering 171 countries and more than…

Intensive insulin regimens have been shown to delay the progression of complications associated with untreated or poorly treated type 1 diabetes (T1D). Therefore, it is unsurprising that insulins…

Each year in the United States, thousands of patients with end-stage renal disease undergo a kidney transplant. To prevent rejection and maintain the new kidney’s functionality, transplant…

Clarivate Epidemiology’s coverage of bladder cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…

Clarivate Epidemiology’s coverage of bladder cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…

Roche/Genentech achieved a clinical and regulatory milestone with the approval of Ocrevus for the treatment of primary-progressive multiple sclerosis (PP-MS), the first of its kind. According to…

Roche / Genentech achieved a clinical and regulatory milestone with the approval of Ocrevus for the treatment of primary-progressive multiple sclerosis (PP-MS)—making it the first agent to…

Obesity is a significant public health concern in the United States. The body of evidence highlighting the physical and economic impact of obesity on society is growing steadily. The most…

Drugs with novel mechanisms of action are needed for the management of psychiatric patients refractory to current therapies (e.g., patients with treatment-resistant depression [TRD], moderate to…

Drugs with novel mechanisms of action are needed for the management of psychiatric patients refractory to current therapies (e.g., patients with treatment-resistant depression [TRD], moderate to…